Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Total Assets
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) holds total assets worth $512.79K USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Liminatus Pharma, Inc. Class A Common St (LIMN) net asset quality to measure how much of total assets are equity-financed.
Liminatus Pharma, Inc. Class A Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's total assets have evolved over time, based on quarterly financial data. Check LIMN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Liminatus Pharma, Inc. Class A Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Liminatus Pharma, Inc. Class A Common Stock's total assets of $512.79K consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Liminatus Pharma, Inc. Class A Common St market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Liminatus Pharma, Inc. Class A Common Stock's current assets represent 97.6% of total assets in 2025, an increase from 0.2% in 2021.
- Cash Position: Cash and equivalents constituted 65.9% of total assets in 2025, up from 0.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Total Assets
Key competitors of Liminatus Pharma, Inc. Class A Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Liminatus Pharma, Inc. Class A Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.21 | 0.08 |
| Quick Ratio | 0.05 | 0.21 | 0.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-9.80 Million | $-19.47 Million | $-4.25 Million |
Liminatus Pharma, Inc. Class A Common Stock - Advanced Valuation Insights
This section examines the relationship between Liminatus Pharma, Inc. Class A Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 10.68 |
| Asset Growth Rate (YoY) | -81.9% |
| Total Assets | $512.79K |
| Market Capitalization | $5.48 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Liminatus Pharma, Inc. Class A Common Stock's assets at a significant premium (10.68x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Liminatus Pharma, Inc. Class A Common Stock's assets decreased by 81.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual total assets of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $512.79K | -81.87% |
| 2024-12-31 | $2.83 Million | -37.17% |
| 2023-12-31 | $4.50 Million | -70.93% |
| 2022-12-31 | $15.49 Million | -94.40% |
| 2021-12-31 | $276.44 Million | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.